Efficacy and Safety of Add-on Therapy With DLBS3233 in Patients With Type-2 Diabetes Mellitus

Inclusion Criteria: * Male subjects with age of 40 - 70 years; or female subjects with age of 55 - 70 years (post-menopause) at screening * Diagnosed with type-2 diabetes mellitus * Have been being treated with a combination of two OHA for at least 3 months prior to screening * A1c level of \>= 7.0 % * Hemoglobin level of \>= 10 g/dL * Body Mass Index (BMI) \> 18.5 kg/m2 * Refuse insulin therapy * Able to take oral medicine Exclusion Criteria: * Subjects with symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia * Uncontrolled hypertension defined as systolic blood pressure \> 160 mmHg and/or diastolic blood pressure \> 100 mmHg * History of or current chronic treatment with insulin * History of renal and/or liver disease * Impaired liver function: serum ALT \> 2.5 times upper limit of normal and positive result of chronic or acute hepatitis B or C test * Impaired renal function: serum creatinine \>= 1.5 times upper limit of normal * Current treatment with systemic corticosteroids or herbal (alternative) medicines * Any other disease state or uncontrolled illness, which judged by the investigator, could interfere with trial participation or trial evaluation * Participation in any other clinical studies within 30 days prior to screening